AGL 37.85 Decreased By ▼ -0.09 (-0.24%)
AIRLINK 160.49 Increased By ▲ 5.27 (3.4%)
BOP 8.95 Decreased By ▼ -0.12 (-1.32%)
CNERGY 6.85 Increased By ▲ 0.13 (1.93%)
DCL 10.10 Increased By ▲ 0.57 (5.98%)
DFML 40.30 Decreased By ▼ -0.01 (-0.02%)
DGKC 92.30 Decreased By ▼ -0.65 (-0.7%)
FCCL 38.10 Decreased By ▼ -0.28 (-0.73%)
FFBL 78.45 Decreased By ▼ -0.13 (-0.17%)
FFL 13.50 Decreased By ▼ -0.10 (-0.74%)
HUBC 113.90 Increased By ▲ 3.71 (3.37%)
HUMNL 14.64 Decreased By ▼ -0.25 (-1.68%)
KEL 5.63 Decreased By ▼ -0.10 (-1.75%)
KOSM 8.25 Decreased By ▼ -0.22 (-2.6%)
MLCF 44.78 Decreased By ▼ -0.88 (-1.93%)
NBP 74.98 Decreased By ▼ -1.19 (-1.56%)
OGDC 192.00 Increased By ▲ 0.13 (0.07%)
PAEL 31.65 Increased By ▲ 1.17 (3.84%)
PIBTL 8.68 Increased By ▲ 0.52 (6.37%)
PPL 166.75 Increased By ▲ 0.19 (0.11%)
PRL 31.25 Increased By ▲ 1.81 (6.15%)
PTC 22.08 Increased By ▲ 2.01 (10.01%)
SEARL 98.30 Increased By ▲ 1.68 (1.74%)
TELE 8.51 Increased By ▲ 0.24 (2.9%)
TOMCL 34.80 Increased By ▲ 0.54 (1.58%)
TPLP 11.12 Increased By ▲ 0.90 (8.81%)
TREET 18.52 Increased By ▲ 0.86 (4.87%)
TRG 60.90 Decreased By ▼ -0.35 (-0.57%)
UNITY 32.00 Increased By ▲ 0.03 (0.09%)
WTL 1.53 Increased By ▲ 0.06 (4.08%)
BR100 11,249 Increased By 33.2 (0.3%)
BR30 33,968 Increased By 317.6 (0.94%)
KSE100 104,886 Increased By 326.8 (0.31%)
KSE30 32,448 Increased By 82.5 (0.26%)

ZURICH: Pharmaceutical giant Novartis said Tuesday it was increasing its full-year sales and profits outlook after strong earnings in the first quarter on the back of a handful of new drugs.

The Swiss drugmaker said that its medicines for heart disease, cancer and multiple sclerosis had buoyed earnings in the quarter.

The group reported a three percent increase in net profit in the first three months of the year to nearly $2.3 billion.

Sales were also up three percent compared to the last three months of 2022 to almost $13 billion.

Drug price adjustment: Pharma industry seeks support of govt

Novartis said that its operating profit would likely increase in the high single-digits this year on the back of strong momentum at the start of the year, while group sales are expected to grow in mid-single digits.

“Novartis delivered strong growth to start 2023, driven by our in-market growth brands, in particular Entresto, Kisqali and Kesimpta,” said the group’s CEO Vas Narasimhan, referring to some of the group’s flagship products.

“Our strong start to the year and confidence in our growth drivers allow us to raise guidance for the full year 2023.”

He said the group would prioritise “high-value” medicines“ across five core areas to drive its productivity, including cardiovascular and neuroscience.

Last year the group slashed around 8,000 jobs worldwide as part of a reorganisation that includes spinning off its generic drug division Sandoz.

Comments

Comments are closed.